We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
16 Aug 2021 - 26 Aug 2021
Virtual Venue

Low Sugar Metabolite Associated with Disability, Neurodegeneration in MS

By LabMedica International staff writers
Posted on 27 May 2021
Print article
Image: AB Sciex 4000Qtrap quadrupole mass spectrometer (Photo courtesy of Sciex)
Image: AB Sciex 4000Qtrap quadrupole mass spectrometer (Photo courtesy of Sciex)
N-glycan branching modulates cell surface receptor availability, and its deficiency in mice promotes inflammatory demyelination, reduced myelination, and neurodegeneration. N-acetylglucosamine (GlcNAc) is a rate-limiting substrate for N-glycan branching.

However, endogenous serum GlcNAc levels in patients with multiple sclerosis (MS) are unknown. MS is characterized by recurrent episodes of neurologic dysfunction resulting from acute inflammatory demyelination. Progressive MS (PMS) is distinguished by continuous inflammation, failure to remyelinate, and progressive neurodegeneration, causing accrual of irreversible neurologic disability.

Neurologists at the University of California, Irvine (Irvine, CA, USA) and their international colleagues conducted a cross-sectional discovery study and cross-sectional confirmatory study at two academic MS centers in the USA and Germany. The discovery study recruited 54 patients with MS from an outpatient clinic as well as 66 healthy controls between April 20, 2010, and June 21, 2013. The confirmatory study recruited 180 patients with MS from screening visits at an academic MS study center between April 9, 2007, and February 29, 2016. Serum samples were analyzed by triple-quadrupole mass spectrometer (AB Sciex 4000Qtrap, Toronto, ON, Canada).

The scientists reported that in the discovery cohort, the mean ± SD, serum level of GlcNAc plus its stereoisomers (N-acetylhexosamine, HexNAc) was 710 ± 174 nM in healthy controls and marginally reduced in patients with relapsing-remitting MS (RRMS) level was 682 ± 173 nM, whereas patients with PMS displayed markedly reduced levels was 548 ± 101 nM compared with healthy controls, and patients with RRMS. The difference between patients with RRMS, 709 ±193 nM and those with progressive MS was 405 ±161 nM, was confirmed in the independent confirmatory cohort. Lower HexNAc serum levels correlated with worse expanded disability status scale scores and correlated with a greater percentage of brain volume loss at 18 months.

Alexander Brandt, MD, adjunct associate professor of neurology and first author of the study, said, “Lower GlcNAc serum marker levels correlated with multiple measures of neurodegeneration in MS, namely worse expanded disability status scale scores, lower thalamic volume, and thinner retinal nerve fiber layer. Also, low baseline serum levels correlated with a greater percentage of brain volume loss at 18 months.”

The authors concluded that their study suggests that deficiency of GlcNAc plus its stereoisomers (HexNAc) may be a biomarker for PMS. Previous preclinical, human genetic, and ex vivo human mechanistic studies revealed that N-glycan branching and/or GlcNAc may reduce proinflammatory responses, promote myelin repair, and decrease neurodegeneration. Combined, the data suggest that GlcNAc deficiency may be associated with progressive disease and neurodegeneration in patients with MS. The study was published on May 10, 2021 in the journal JAMA Neurology.

Related Links:
University of California, Irvine

Gold Supplier
Gold Supplier
SARS-CoV-2 Genome RNA Controls
Molecular Diagnostic System
PCR System
Biomark HD

Print article


Molecular Diagnostics

view channel
Image: The Lumipulse G β-amyloid 1-40 assay kit (Photo courtesy Fujirebio)

APOE Gene Influences Alzheimer's Symptoms, Biomarkers in Down Syndrome

Individuals with Down syndrome (DS) constitute a population at ultrahigh risk of developing Alzheimer disease (AD) because of trisomy of chromosome 21, which harbors the amyloid precursor protein (APP) gene.... Read more


view channel

ELITechGroup Acquires Freezing Point Osmometry Provider GONOTEC

ELITechGroup (Puteaux, France) has acquired GONOTEC (Berlin, Germany), thus uniting two osmometry market leaders. The acquisition will also provides the industry with a full range of osmometry solutions... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.